Trial Profile
A Phase 3, Short-Term, Multicenter, Placebo-Controlled, Randomized Withdrawal Study of LY2140023 Monohydrate in Patients With DSM-IV-TR Schizophrenia
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 16 Sep 2022
Price :
$35
*
At a glance
- Drugs Pomaglumetad methionil (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Pharmacogenomic; Registrational
- Sponsors Eli Lilly and Company
- 29 Aug 2012 Status changed from recruiting to discontinued, according to an Eli Lilly media release.
- 02 Aug 2012 Planned End Date changed from 1 Nov 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.
- 18 Jun 2012 Planned end date changed from 1 Dec 2012 to 1 Nov 2012 as reported by ClinicalTrials.gov.